Racura Oncology Ltd (ASX:RAC) shares closed at A$2.05, down A$0.05 or 2.38% at the close of 12 August 2026. The clinical-stage cancer biotech, formerly known as Race Oncology, adopted the Racura Oncology name in December 2025 while retaining its ASX ticker RAC. The company is advancing bisantrene across several oncology programs, with a planned Phase 3 acute myeloid leukaemia (AML) trial representing a major upcoming development.

What happened to Racura Oncology shares?

Racura remains a thinly traded and volatile name on the ASX healthcare board, meaning significant daily movements can occur as investors respond to company developments and broader biotechnology sentiment.

Racura closed at A$2.05 on 12 August 2026, down 2.38% for the session. The latest movement comes as the company progresses its clinical programs and prepares for the next stage of its development.

What is driving the story?

The core Business remains centred on bisantrene, an older chemotherapy agent historically marketed as Zantrene, which the company has reformulated and is advancing as a proprietary anti-cancer asset. Management describes Racura as a Phase 3 clinical biopharmaceutical company.

The company is pursuing three clinical pillars: a program in acute myeloid leukaemia (AML), a combination approach in EGFR-mutant non-small cell lung cancer, and a cardioprotection program designed to protect the heart from damage associated with doxorubicin-based chemotherapy.

The AML program is the headline development, with a Phase 3 trial flagged to begin enrolling patients in the second half of 2026. Its progress could represent an important transition point for the company as it moves towards later-stage clinical development.

The December 2025 rebrand to Racura Oncology marked a new phase for the business. The progress of its clinical programs, rather than the change in corporate identity itself, will determine the next stage of the company's development.

Latest ASX announcements

Recent disclosures have centred on funding and capital-management activities as the company prepares to advance its clinical programs. Racura has issued new stock Options and sought ASX Quotation for additional shares.

Across roughly two years, the company has assembled approximately A$34.3 million through option conversions, private placements and option underwriting. Management has indicated that the funds are intended to support its three clinical programs and general working capital.

The continued use of equity-based funding is an important part of the company's development model as it progresses towards later-stage clinical trials.

Financial position

As a pre-revenue developer, Racura's financial position is primarily determined by its cash reserves and expenditure on clinical development. The company reported cash reserves of approximately A$19.38 million at 31 March 2026.

That provides funding for the company's current activities, but a Phase 3 clinical program can require substantial expenditure. Further Capital raising may therefore form part of the company's future funding requirements as clinical development progresses.

Bull case

The bull case rests on the potential of bisantrene across multiple high-unmet-need indications. Racura is developing the asset across AML, lung cancer and cardioprotection, creating several potential pathways for clinical progress.

The planned move into a Phase 3 AML trial is particularly significant. If the trial begins enrolment as planned and subsequent clinical developments support the program, it could provide an important validation point for the company's broader development strategy.

Bear case

The bear case is that Racura remains a pre-revenue biotech whose prospects depend heavily on clinical outcomes. Earlier-stage results do not guarantee success in later-stage trials, and clinical development can face delays, unexpected results or additional funding requirements.

The company also needs capital to continue advancing its programs. Further Equity issuance could increase the number of shares on issue, while a deterioration in biotechnology-market sentiment could make future funding more challenging.

What could move the shares next?

The major potential catalyst is the commencement of the Phase 3 AML program flagged for the second half of 2026. Enrolment milestones, developments from the lung cancer combination program and progress on the cardioprotection program could also influence sentiment.

On the funding side, investors will be watching quarterly cash-flow reports, option activity and any additional capital raising as the company progresses its clinical pipeline.

Bottom line

Racura Oncology is a clinical-stage biotechnology company developing bisantrene across AML, lung cancer and cardioprotection programs. The December 2025 rebrand from Race Oncology marked a new chapter, while the planned Phase 3 AML program represents the most important upcoming development.

The shares closed at A$2.05 on 12 August 2026, down 2.38% for the session. The company's future trajectory will depend on clinical execution, progress towards the Phase 3 program and its ability to maintain adequate funding as development advances.